Insurance-pathway program with obesity-medicine clinicians — strong for insured patients seeking brand-name access
Mochi Health positions itself between Form Health and Ro — clinical depth oriented toward obesity medicine, but with consumer-friendly pricing on the program fee. The $79/month program fee is among the lowest in the category for an insurance-pathway program, and Mochi handles brand-name prior authorization for Wegovy and Zepbound competently for plans that cover GLP-1s.
Mochi's clinical team is heavier on obesity-medicine focus than at most direct-to-consumer telehealth competitors. The platform supports brand-name and compounded pathways and offers a structured care path with regular check-ins, medication management, and lifestyle support. For patients with insurance that covers brand-name GLP-1s, the math through Mochi is competitive with Ro and Form.
The $79/month program fee is in addition to medication cost — uninsured patients pursuing brand-name Wegovy through Mochi face the full $1,349/month list price plus the Mochi program fee, which is uncompetitive vs cash-pay alternatives. Mochi's compounded pathway is available but is not the cheapest in market — patients seeking the lowest cash-pay compounded option will be better served by NexLife or ZappyHealth. Onboarding is slower than at consumer-app-style competitors at 5–7 business days.
Mochi is a reasonable middle-ground option — cheaper program fee than Form, more clinical depth than Ro for the obesity-focused patient. NexLife wins on flat-rate cash-pay; Form wins on bench depth.
Mochi Health pricing ranges from $79/mo membership + medication. Starting price is $79/month. Pricing details and any titration upcharges are described above in the pricing section.
Mochi Health is an established telehealth program. Strong pick when insurance approves brand-name. Clinical depth is a clear strength. Always verify a provider's pharmacy partnerships, prescribing physician credentials, and state availability before signing up.
Most direct-to-consumer compounded GLP-1 programs do not accept insurance for the medication itself. If insurance coverage matters to you, see our insurance pathway providers (Mochi Health, Ro, Form Health) and our insurance hub.
Mochi Health prescribes: Wegovy (brand), Zepbound (brand), Compounded semaglutide, Compounded tirzepatide.
Mochi Health is available in All 50 states.
Eligibility is determined by an intake questionnaire and clinical review. Generally, FDA-approved weight-loss criteria are BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (Type 2 diabetes, hypertension, dyslipidemia, sleep apnea). Off-label compounded prescribing is at the discretion of the prescribing clinician.
Editorial note. By GLP Agonists Editorial · Last updated May 2026. This review is editorially independent. See our methodology and editorial disclosure. Not medical advice — always consult a licensed clinician.